Key result
TNF-alpha pre-treatment of MSCs boosts engraftment and improves cardiac function after experimental MI.
Why the study?
TNF-alpha released after acute MI modulates cytokines and adhesion molecules that may influence mesenchymal stem cell engraftment in infarcted myocardium.
Does pre-treatment of mesenchymal stem cells with TNF-alpha improve engraftment and recovery of cardiac function in experimental myocardial infarction?
Does pre-treatment of mesenchymal stem cells with TNF-alpha improve engraftment and recovery of cardiac function in experimental myocardial infarction?
Pre-treating mesenchymal stem cells with TNF-alpha prior to transplantation enhances their engraftment and improves cardiac function recovery in experimental myocardial infarction.
TNF-alpha released from ischemic heart after acute MI increases the production of other cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6) and adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1). Activation of nuclear factor kappa B (NF-kappa B) by TNF-alpha , up-regulates the expression of molecules which are involved in inflammation and cell adhesion. For these reasons, we assessed the extent that treatment of MSC with tumor necrosis factor (TNF)-alpha modifies the characteristics of MSC, important to their engraftment in experimental myocardial infarct. Here, we show that pre-treatment of MSC prior to transplantation with tumor necrosis factor (TNF)-alpha increases adhesiveness, and migration of MSC in vitro and leads to increased expression of bone morphogenetic protein (BMP)-2 by MSC. Moreover, this treatment increases the rate of engraftment of MSC and improves recovery of cardiac function after myocardial infarction. These insights might provide better strategies for the treatment of myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Yong Sook Kim (2009) studied Myocardial infarction. Pre-treatment of mesenchymal stem cells (MSC) with tumor necrosis factor (TNF)-alpha was evaluated on Engraftment of MSC and recovery of cardiac function. Pre-treatment of mesenchymal stem cells with TNF-alpha prior to transplantation increased engraftment rates and improved recovery of cardiac function after experimental myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: